4668629 Human hybridomas, precursors and products

4668629 Human hybridomas, precursors and products

PATENT ABSTRACTS 306 4668618 4668629 NUCLEAR ISOLATION MEDIUM AND PROCEDURE FOR SEPARATING CELL NUCLEI HUMAN HYBRIDOMAS, PRECURSORS AND PRODUCTS ...

62KB Sizes 1 Downloads 49 Views

PATENT ABSTRACTS

306

4668618

4668629

NUCLEAR ISOLATION MEDIUM AND PROCEDURE FOR SEPARATING CELL NUCLEI

HUMAN HYBRIDOMAS, PRECURSORS AND PRODUCTS

Jerry T Thornthwaite Nuclear isolation media and procedures are described for dissociating discrete, nonagglomerated cell nuclei from animal tissue without the need to use enzyme treatments, centrifugation or the like in order to achieve the desired separation. The media facilitates separation and maintains the nuclear membrane intact and in its normal physiological environment. When a DNA-fluorochrome stain is included in the medium an essentially one step combination nuclear isolation and DNA staining procedure is used to measure DNA in tissue cells by flow cytometry. Rapid and consistent results are obtained and multiple sampling of the same tissue or comparison between whole tissues and their single cell isolates are also described.

Henry S Kaplan. Lennart Olsson assigned to The Board of Trustees of Leland Stanford Jr Universit3 Human monoclonal antibody compositions, human-human monoclonal hybridoma cells, human myeloma cells, human antibody genes and their uses. Human myeloma cells are developed for fusing with immunized lymphoid cells to provide stable human-human hybridoma strains producing complete monoclonal antibodies for a predefined antigen. From a myeloma cell line, rapidly growing 8-azaguanine resistant HAT sensitive cells are selected. The selected myeloma cells are crossed with immunized lymphoid cells and the resulting cell mixture grown under controlled selective conditions. After expansion of the desired hybridoma cells, the monoclonal antibodies may be harvested. The hybridomas serve as a source for messenger RNA for light and heavy chains which may be used for production of light and heavy chain immunoglobulin proteins through hybrid DNA techniques.

4668631 4668624 PROTEIN TRANSLATION METHOD Bryan Roberts assigned to E 1 Du Pont de Nemours and Company An improved method for in vitro synthesis of protein by in vivo processes in an extract from a living organism and containing endogenous ribosomes and endogenous transfer RNA, primarily from endogenous amino acids in said extract primarily by the use of a predetermined exogenous messenger ribonucleic acid (mRNA). An improved method of assaying such a synthesis by the use of a labelled amino acid. which is present during said synthesis and is incorporated into said protein. A kit for carrying out such synthesis and assay comprising a vial of substantially prokaryotic and eukaryotic cellfree extract from a living organism containing endogenous ribosomes, endogenous transfer RNA and endogenous amino acids, a vial containing translation cocktail for promoting the synthesis, and a vial containing control messenger RNA.

PROCESS FOR PRODUCING RESTRICTION ENZYME

A

Akira Obayashi, Nobutsug Hiraoka. Keiko Kita, Hiroshi Nakajima, Uji, Japan assigned to Takara Shuzo Co Ltd A restriction endonuclease having the ability to recognize the same base sequence and cleavage sites as Sacll and Sstll can be produced from Gluconobacter and isolated in pure form because no other restriction enzyme is formed.

4668777 PHOSPHORAMIDITE NUCLEOSIDE COMPOUNDS Marvin H Caruthers, Serge Beaucage assigned to University Patents Inc A new class of nucleoside phosphoramidites which are relatively stable to permit isolation thereof and storage at room temperature. The phosphoramidites are derivatives of saturated secondary amines.